Mogroside IIIe has anti-inflammatory activity, it attenuates LPS-induced acute lung injury in mice partly through regulation of the TLR4/MAPK/NF-κB axis via AMPK activation. It also has anti-fibrotic activity, it reduces pulmonary fibrosis through Toll-Like receptor 4 pathways.